Summit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC Subpopulation

Morsa Images Summit Therapeutics (NASDAQ:SMMT) and its partner in China Akeso just announced positive data from its phase 3 HARMONi-2 study, which used its PD-1/VEGF bispecific antibody ivonescimab for the treatment of patients with locally advanced or metastatic non-small cell lung cancer [NSCLC] who have positive PD-L1 expression. This is the first drug candidate that has gone toe to toe with Merck (MRK) Keytruda for the treatment of this patient population. That is, ivonescimab is the first type of drug ...